Bacteria hits heart drug effectiveness - researchers

Last updated 11:39 23/05/2011

Relevant offers

Health

Health minister officially opens Taranaki's $3.6m angiography suite Rates cut and $200,000 business recovery package for gastro-hit Havelock North Search for gastro source homing in on bores and nearby Mangateretere Stream All Blacks visit epilepsy sufferers at Wellington Hospital ahead of Bledisloe Cup Positive future for Auckland teenager who had pioneering heart surgery Hamilton City Council's water supply safe: staff Candidates hedge bets over water fluoridation Poisoning the wells: a history of infected drinking water in Canterbury Second elderly woman dies after contracting campylobacter in outbreak Kiwis in world's largest study into clinical antidepressant use of 'club drug' ketamine

Maori and Pacific Islanders' exposure to the bacteria that causes rheumatic fever means the standard heart drug streptokinase is likely to be less effective when they have heart attacks, say University of Otago researchers.

High rates of Group A streptococcal infection, the same infection which leads to rheumatic fever, meant many people would have antibodies to the drug, said Garry Nixon from the Department of General Practice and Rural Health in Dunedin.

"There's therefore a real risk that when they have a heart attack and are given this drug it will not work for them," he said.

The findings are in a University of Otago study, recently published in the British Medical Journal Clinical Pathology, and confirms Australian research that indigenous people with heart problems are more likely to have resistance to streptokinase - which is used to dissolve clots in arteries.

The study of 180 heart attack patients from the Hokianga, Thames and Central Otago showed the rural Hokianga community - with the highest proportion of Maori and lowest socio-economic status - had resistance to streptokinase medication 2.8 times higher than in Central Otago, which had the lowest proportion of Maori and higher socio-economic status, Nixon said.

That meant that newer fibrinolytic heart drugs, although more expensive, should be used for patients with heart attacks in predominantly Maori rural communities, he said.

Nixon said the study was a timely reminder of the need to exercise caution when translating the results of drug trials carried out on Caucasians to other ethnic groups such and Maori and Pacific Islanders.

People living in Samoa, the Cook Islands, French Polynesia and Tonga have some of the highest rates of rheumatic fever in the world.

Pacific Islanders living in New Zealand are 1.5 to 2 times more likely to have rheumatic fever than Maori.

Ad Feedback

- NZPA

Special offers
Opinion poll

Should fluoride in water be the responsibility of central government?

Yes

No

Vote Result

Featured Promotions

Sponsored Content